查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1435018

抗體藥物複合體契約製造市場：按連結器、條件和最終用途分類 - 2024-2030 年全球預測

Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗體藥物複合體契約製造市場規模為118.8億美元，2024年達130.6億美元，2030年達259.9億美元，複合年成長率為11.82%。

抗體藥物複合體契約製造的全球市場

主要市場統計
基準年[2023] 118.8億美元
預測年份 [2024] 130.6億美元
預測年份 [2030] 259.9億美元
複合年成長率（%） 11.82%
抗體藥物偶聯物的合約製造市場-IMG1

FPNV定位矩陣

FPNV 定位矩陣對於評估抗體藥物複合體契約製造市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗體藥物複合體契約製造市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-抗體藥物複合體契約製造市場的市場規模和預測是多少？

2-在抗體藥物複合體契約製造市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-抗體藥物複合體契約製造市場的技術趨勢和法律規範是什麼？

4-抗體藥物複合體契約製造市場主要供應商的市場佔有率是多少？

5-進入抗體藥物複合體契約製造市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 生物製藥公司外包增加
      • CMO 數量快速增加以及持續的研發活動
      • 隨著慢性病盛行率的增加，對 ADC 的需求也隨之增加
    • 抑制因素
      • 建立抗體藥物複合體的生產設施非常昂貴。
    • 機會
      • 監管機構對 ADC 的核准迅速增加
      • 擴大先進製造技術投資
    • 任務
      • 對 CMO 的嚴格監管要求
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第 6 章 Linker 的抗體藥物複合體契約製造市場

  • 可切割
  • 不可切割的

第7章依條件分類的抗體藥物複合體契約製造市場

  • 乳癌
  • 淋巴瘤
  • 骨髓瘤

第8章抗體藥物複合體契約製造市場：依最終用途分類

  • 臨床試驗
  • 骨髓瘤治療

第9章北美和南美抗體藥物複合體契約製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太抗體藥物複合體契約製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：歐洲、中東和非洲抗體藥物複合體的契約製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • AbbVie Inc.
    • ADC Therapeutics SA.
    • AstraZeneca PLC
    • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
    • Axplora
    • Catalent, Inc.
    • Creative Biolabs
    • Daiichi Sankyo
    • EirGenix, Inc.
    • Gilead Sciences
    • GlaxoSmithKline PLC
    • ImmunoGen, Inc.
    • Merck KgaA
    • Mersana Therapeutics
    • MicroBiopharm Japan Co., Ltd.
    • Pfizer Inc.
    • Pierre Fabre SA
    • Piramal Pharma Solutions
    • Recipharm AB
    • Regeneron Pharmaceuticals, Inc.
    • Samsung Biologics
    • Sanofi
    • Sartorius AG
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-B16853777721

[193 Pages Report] The Antibody Drug Conjugates Contract Manufacturing Market size was estimated at USD 11.88 billion in 2023 and expected to reach USD 13.06 billion in 2024, at a CAGR 11.82% to reach USD 25.99 billion by 2030.

Global Antibody Drug Conjugates Contract Manufacturing Market

KEY MARKET STATISTICS
Base Year [2023] USD 11.88 billion
Estimated Year [2024] USD 13.06 billion
Forecast Year [2030] USD 25.99 billion
CAGR (%) 11.82%
Antibody Drug Conjugates Contract Manufacturing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Drug Conjugates Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Drug Conjugates Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugates Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADC Therapeutics SA., AstraZeneca PLC, Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories, Axplora, Catalent, Inc., Creative Biolabs, Daiichi Sankyo, EirGenix, Inc., Gilead Sciences, GlaxoSmithKline PLC, ImmunoGen, Inc., Merck KgaA, Mersana Therapeutics, MicroBiopharm Japan Co., Ltd., Pfizer Inc., Pierre Fabre S.A, Piramal Pharma Solutions, Recipharm AB, Regeneron Pharmaceuticals, Inc., Samsung Biologics, Sanofi, and Sartorius AG.

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugates Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Linker
    • Cleavable
    • Non-cleavable
  • Condition
    • Breast Cancer
    • Lymphoma
    • Myeloma
  • End Use
    • Clinical Trial
    • Myeloma Treatment
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Drug Conjugates Contract Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Drug Conjugates Contract Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Antibody Drug Conjugates Contract Manufacturing Market?

4. What is the market share of the leading vendors in the Antibody Drug Conjugates Contract Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Antibody Drug Conjugates Contract Manufacturing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antibody Drug Conjugates Contract Manufacturing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing outsourcing by biopharmaceutical companies
      • 5.1.1.2. Surging number of CMOs and ongoing R&D activities
      • 5.1.1.3. Growing demand for ADC amid high prevalence of chronic disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of setting up a production facility for antibody-drug conjugates
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in ADC approvals from regulatory bodies
      • 5.1.3.2. Expanding investments in advanced manufacturing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for CMOs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antibody Drug Conjugates Contract Manufacturing Market, by Linker

  • 6.1. Introduction
  • 6.2. Cleavable
  • 6.3. Non-cleavable

7. Antibody Drug Conjugates Contract Manufacturing Market, by Condition

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Lymphoma
  • 7.4. Myeloma

8. Antibody Drug Conjugates Contract Manufacturing Market, by End Use

  • 8.1. Introduction
  • 8.2. Clinical Trial
  • 8.3. Myeloma Treatment

9. Americas Antibody Drug Conjugates Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AbbVie Inc.
    • 13.1.2. ADC Therapeutics SA.
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
    • 13.1.5. Axplora
    • 13.1.6. Catalent, Inc.
    • 13.1.7. Creative Biolabs
    • 13.1.8. Daiichi Sankyo
    • 13.1.9. EirGenix, Inc.
    • 13.1.10. Gilead Sciences
    • 13.1.11. GlaxoSmithKline PLC
    • 13.1.12. ImmunoGen, Inc.
    • 13.1.13. Merck KgaA
    • 13.1.14. Mersana Therapeutics
    • 13.1.15. MicroBiopharm Japan Co., Ltd.
    • 13.1.16. Pfizer Inc.
    • 13.1.17. Pierre Fabre S.A
    • 13.1.18. Piramal Pharma Solutions
    • 13.1.19. Recipharm AB
    • 13.1.20. Regeneron Pharmaceuticals, Inc.
    • 13.1.21. Samsung Biologics
    • 13.1.22. Sanofi
    • 13.1.23. Sartorius AG
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DYNAMICS
  • FIGURE 7. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2030 (%)
  • FIGURE 8. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2030 (%)
  • FIGURE 10. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 12. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 57. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 66. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 69. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 72. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 85. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 88. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 91. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 94. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 97. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 100. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 103. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 106. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 109. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 112. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 115. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 118. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 124. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 127. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 133. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 142. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 143. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET LICENSE & PRICING